A1 Refereed original research article in a scientific journal
A 6-Year Single-Center Experience of Intra-aortic Balloon Pump Treatment-Retrospective Analysis of 223 Patients.
Authors: Saura E, Savola J, Gunn J
Publication year: 2015
Journal: Journal of Cardiothoracic and Vascular Anesthesia
Volume: 29
Issue: 6
First page : 1410
Last page: 1414
Number of pages: 5
ISSN: 1053-0770
DOI: https://doi.org/10.1053/j.jvca.2015.04.014
OBJECTIVES:
This study describes the long-term survival (1 year) of patients after intra-aortic balloon pump (IAPB) treatment.
DESIGN:
A single-center, retrospective registry study.
SETTING:
Single university hospital intensive care unit.
PARTICIPANTS:
Participants included 223 consecutive patients who received intra-aortic balloon pump (IABP) treatment between January 1, 2005, and December 31, 2010 (203 cardiac surgical patients [7.8% of all cardiac surgical patients] and 20 conservative medical patients).
INTERVENTIONS:
IABP treatment was used as an adjunct therapy for severe hemodynamic compromise perioperatively in cardiac surgery and in hemodynamic shock of other etiology.
MEASUREMENTS AND MAIN RESULTS:
Mean age of patients was 66±10 years. The 30-day mortality was 22.1% for surgical patients and 37.8% for conservative medical patients. The 1-year mortality was 24.5% for surgical patients and 55% for conservative medical patients. There were 14 (6.3%) major complications related to IABP treatment that required operative treatment. The 1-year survival for patients surviving the initial 30 days after coronary artery bypass grafting was 95.2%. Independent predictors of 1-year mortality (Cox regression) were age, previous cardiac surgery, critical preoperative state, and conservative medical treatment. Timing (preoperative, intraoperative, postoperative) of IABP treatment did not predict survival.
CONCLUSIONS:
IABP treatment was safe with few serious complications. Timing of IABP placement was not related to survival. Survival at 1-year follow-up was excellent after an initially high mortality for cardiac surgical patients treated for hemodynamic compromise with aortic counterpulsation.